TEVA-AZITHROMYCIN DIN 02267845
Status: Marketed
Holder: TEVA CANADA LIMITED
Health Canada record
| Active ingredient(s) | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01FA10 AZITHROMYCIN |
| Original market date | 01-Dec-2005 |
| Current status date | 03-Mar-2017 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02363364 | AVA-AZITHROMYCIN | AVANSTRA INC | Tablet | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250 MG | Cancelled Post Market |
| 02282429 | DOM-AZITHROMYCIN | DOMINION PHARMACAL | Powder For Suspension | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 100 MG | Cancelled Pre Market |
| 02282437 | DOM-AZITHROMYCIN | DOMINION PHARMACAL | Powder For Suspension | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 200 MG | Cancelled Pre Market |
| 02278502 | DOM-AZITHROMYCIN | DOMINION PHARMACAL | Tablet | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 600 MG | Cancelled Post Market |
| 02278499 | DOM-AZITHROMYCIN | DOMINION PHARMACAL | Tablet | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250 MG | Cancelled Post Market |
| 02278359 | MYLAN-AZITHROMYCIN | MYLAN PHARMACEUTICALS ULC | Tablet | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250 MG | Cancelled Post Market |
| 02315157 | NOVO-AZITHROMYCIN PEDIATRIC | TEVA CANADA LIMITED | Powder For Suspension | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 100 MG | Cancelled Post Market |
| 02315165 | NOVO-AZITHROMYCIN PEDIATRIC | TEVA CANADA LIMITED | Powder For Suspension | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 200 MG | Cancelled Post Market |
| 02282380 | PHL-AZITHROMYCIN | PHARMEL INC | Powder For Suspension | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 100 MG | Cancelled Post Market |
| 02278588 | PHL-AZITHROMYCIN | PHARMEL INC | Tablet | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250 MG | Cancelled Post Market |
| 02278596 | PHL-AZITHROMYCIN | PHARMEL INC | Tablet | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 600 MG | Cancelled Pre Market |
| 02282410 | PHL-AZITHROMYCIN | PHARMEL INC | Powder For Suspension | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 200 MG | Cancelled Post Market |
| 02275287 | RATIO AZITHROMYCIN | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | Tablet | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 250 MG | Cancelled Post Market |
| 02270358 | SANDOZ AZITHROMYCIN | SANDOZ CANADA INCORPORATED | Tablet | AZITHROMYCIN (AZITHROMYCIN MONOHYDRATE HEMIETHANOLATE) 500 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32533 | 2024-01-17 | Supplement to an Abbreviated New Drug Submission (SANDS) | Update to the Product Monograph. Product Monograph reformatted to the Master Template. Update to the Package Insert |
| 15397 | 2014-03-07 | Abbreviated New Drug Submission (ANDS) | MANUFACTURER NAME CHANGE |
| 7592 | 2005-11-04 | Abbreviated New Drug Submission (ANDS) |